



Prior Authorization Approval Criteria

Abilify (aripiprazole)

Generic name: aripiprazole

Brand name: Abilify

Medication class: Antipsychotic

FDA-approved uses:

- For use in adults and adolescents, 13 years of age or older, with schizophrenia.
- Treatment of acute manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients aged 10 to 17 years
- For use in adults with major depressive disorder (MDD)

Usual dose range:

Schizophrenia – adults	10 mg-30 mg/day
Schizophrenia – adolescents	2 mg-30 mg/day
Bipolar mania – adults	15 mg-30 mg/day
Bipolar mania – pediatric patients	2 mg-30 mg/day
As an adjunct to antidepressants for the treatment of major depressive disorder	2 mg-15 mg/day

Duration of therapy: Indefinite

Criteria for use for schizophrenia or acute bipolar mania (*bullet points below are all inclusive unless otherwise noted*):

- Must have one of the following clinically diagnosed conditions:
 - Schizophrenia and at least 13 years of age or older
- **OR**
- Acute bipolar mania, including manic and mixed episodes associated with bipolar disorder and at least 10 years of age or older
- Must have tried and failed or been intolerant to at least 2 formulary atypical antipsychotic agents

Criteria for Use for MDD (*bullet points below are all inclusive unless otherwise noted*):

- Must have clinically diagnosed MDD.
- Must have failed or been intolerant to at least 3 other antidepressant therapies (ADT).
- Must be used as adjunctive or add-on treatment to ADT and not as monotherapy.
- Must be 18 years of age or older.

Contraindications:

- Known hypersensitivity to aripiprazole.

Not approved if:

- Patient has any contraindications to the use of aripiprazole
- Patient does not meet the above stated criteria.
- No other medication has been utilized.
- Past history of neuroleptic malignant syndrome.
- Past history of seizures.

- Current development of tardive dyskinesia, unless no other choice available.
- Doses needed are higher than 30 mg/day.
- Current history of orthostatic hypotension.
- Patients has dementia-related psychosis.

Special considerations:

Black box warning:

- Children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders are at increased risk of suicidal thinking and behavior.
- Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 11/12/04
First revision: 01/01/05
Second revision: 12/12/07
Third revision: 03/12/08